Improving treatment of depression in the elderly: two innovations in statistical design of clinical trials.
Depression in the elderly patient may present special challenges for the design of clinical treatment trials due to a complex antidepressant treatment history, individual contraindications to certain medications, medical comorbidity, as well as concurrent medications for other medical conditions. The chronic, relapsing, and remitting nature of depression calls for a dynamic, adaptive treatment strategy, matching treatment changes to patient responses. To market a drug successfully in a cost-conscious environment, it also may be necessary to define the unique contribution that a new drug makes to the treatment of patients, in addition to proving that it is efficacious (by comparison to placebo). These issues, although not unique to the elderly, take on greater importance and weight as patient populations age. This article describes 2 innovations in clinical trials design that may help deal with these issues.
Lavori
Philip W
PW
VA Cooperative Studies Program, Palo Alto Coordinating Center and Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA. lavori@stanford.edu
D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D017063:Outcome Assessment, Health Care; D012107:Research Design
D000928:Antidepressive Agents